ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

エファビレンツ

Efavirenz

HCID 64139
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
154598-52-4
標準SMILES
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1
InChIKey
XPOQHMRABVBWPR-ZDUSSCGKSA-N
分子式
C14H9ClF3NO2
平均分子量
315.67 g/mol
単同位体質量
315.0273907

概要

Efavirenz is 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection. It has a role as an antiviral drug and a HIV-1 reverse transcriptase inhibitor. It is an organochlorine compound, an organofluorine compound, a benzoxazine, a member of cyclopropanes and an acetylenic compound.

名称と識別子

優先名称
Efavirenz
IUPAC
(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
現地名
エファビレンツ
英語名
Efavirenz
分子式
C14H9ClF3NO2
分子量
315.67

名称と別名

efavirenz154598-52-4SustivaStocrinDMP-266(-)-EfavirenzViradayEfavirenz teva(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one(4S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-oneEfavirenzumL-743726
名称をさらに表示
エファビレンツ(4S)-6-クロロ-4-(2-シクロプロピルエチニル)-1,4-ジヒドロ-4-(トリフルオロメチル)-2H-3,1-ベンゾオキサジン-2-オン(S)-エファビレンツエファビレンツ (JAN)(4S)-4-(シクロプロピルエチニル)-4-(トリフルオロメチル)-6-クロロ-1,4-ジヒドロ-2H-3,1-ベンゾオキサジン-2-オン(4S)-4α-(トリフルオロメチル)-4-(シクロプロピルエチニル)-6-クロロ-1,2-ジヒドロ-4H-3,1-ベンゾオキサジン-2-オンストックリン(4S)-6-クロロ-4-(2-シクロプロピルエチニル)-4-(トリフルオロメチル)-2,4-ジヒドロ-1H-3,1-ベンゾオキサジン-2-オン(4S)-6-クロロ-4-(シクロプロピルエチニル)-4-(トリフルオロメチル)-1,4-ジヒドロ-2H-3,1-ベンゾオキサジン-2-オンエファビレンズ(4S)-6-クロロ-4α-(トリフルオロメチル)-4-(シクロプロピルエチニル)-1,4-ジヒドロ-2H-3,1-ベンゾオキサジン-2-オンススチバEFVEfavirenz-D5AntiretroviralMDP-266DMP 266Efeveren
DTXSID9046029L-743,726efavirenz, (S)-NSC-742403Sustiva 600JE6H2O27P8(S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-oneTELURA COMPONENT EFAVIRENZ

物性

構造計算による物性

XLogP
4
極性表面積
38.3 Ų
水素結合供与体数
1
水素結合受容体数
5
回転可能結合数
1
重原子数
21
形式電荷
0
複雑度
519

実験および物理化学的性質

Drugs · 3 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals -> Anti infectives for systemic use -> Antivirals for systemic use

LogP4.6
Color/Form · 2 件

Crystals from toluene:heptane

White to slightly pink crystalline powder

Solubility · 2 件

Practically insoluble in water (less than 10 mg/L)

8.55e-03 g/L

Human Drugs · 5 件

Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antiviral Agents; Anti-HIV Agents; Anti-Retroviral Agents; Reverse Transcriptase Inhibitors

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

Melting Point · 3 件

139-141 °C

139-141 °C

139 - 141 °C

Physical DescriptionSolid
Dissociation ConstantspKa = 10.2

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H302 (52.3%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P264, P264+P265, P270, P273, P280, P301+P317, P305+P351+P338, P318, P319, P330, P337+P317, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 88 reports by companies from 13 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

FDA Requirements · 1 件

The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including efavirenz, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Hazard Classes and CategoriesAcute Tox. 4 (52.3%)

安全と保護具

Storage ConditionsCommercially available efavirenz capsules and tablets should be stored at a controlled room temperature of 25 °C, but may be exposed to temperatures ranging from 15-30 °C.
Disposal Methods · 1 件

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.

毒性情報

化学と産業

薬理情報

ATC Code · 4 件

J05AG03

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

J05AG03

Protein Binding99.5-99.75%
Pharmacodynamics · 1 件

Efavirenz (dideoxyinosine, ddI) is an oral non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a synthetic purine derivative and, similar to zidovudine, zalcitabine, and stavudine. Efavirenz was originally approved specifically for the treatment of HIV infections in patients who failed therapy with zidovudine. Currently, the CDC recommends that Efavirenz be given as part of a three-drug regimen that includes another nucleoside reverse transcriptase inhibitor (e.g., lamivudine, stavudine, zidovudine) and a protease inhibitor or efavirenz when treating HIV infection.

Mechanism of Action · 2 件

Similar to zidovudine, efavirenz inhibits the activity of viral RNA-directed DNA polymerase (i.e., reverse transcriptase). Antiviral activity of efavirenz is dependent on intracellular conversion to the active triphosphorylated form. The rate of efavirenz phosphorylation varies, depending on cell type. It is believed that inhibition of reverse transcriptase interferes with the generation of DNA copies of viral RNA, which, in turn, are necessary for synthesis of new virions. Intracellular enzymes subsequently eliminate the HIV particle that previously had been uncoated, and left unprotected, during entry into the host cell. Thus, reverse transcriptase inhibitors are virustatic and do not eliminate HIV from the body. Even though human DNA polymerase is less susceptible to the pharmacologic effects of triphosphorylated efavirenz, this action may nevertheless account for some of the drug's toxicity.

Efavirenz diffuses into the cell where it binds adjacent to the active site of reverse transcriptase. This produces a conformational change in the enzyme that inhibits function.

Biological Half-Life · 3 件

40-55 hours

The terminal elimination half-life of efavirenz is prolonged in patients with chronic liver disease. Following oral administration of a single 400-mg dose of efavirenz, an elimination half-life of 152 or 118 hours was reported in individuals with or without chronic liver disease, respectively.

関連反応

124 件
反応記録を作成
HRID 389408 の反応式
HRID 389408生成物として
HRID 389410 の反応式
HRID 389410生成物として
HRID 389411 の反応式
HRID 389411生成物として
HRID 389413 の反応式
HRID 389413生成物として
HRID 582912 の反応式
HRID 582912生成物として
HRID 659726 の反応式
HRID 659726生成物として
HRID 659728 の反応式
HRID 659728生成物として
HRID 659729 の反応式
HRID 659729生成物として
前へ1 / 16 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
154598-52-4
PubChem CID
64139
DTXSID
DTXSID9046029
ChEMBL
CHEMBL223228
ChEBI
CHEBI:119486
UNII
JE6H2O27P8
EC Number
620-492-6
Nikkaji
J727.577C
Collision Cross Section
168.1 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Dataset: TOXCAST; Source Identifier: DTXSID9046029]

物理化学的性質

融点
139 · 139-141°C
比旋光度
20 · D20 -84.7° (c = 0.005 g/ml in CH3Cl); D25 -94.1° (c = 0.300 in methanol)
沸点
340.6 · 340.6±42.0 °C(Predicted)
比重(密度)
1.53 · 1.53±0.1 g/cm3(Predicted)
闪点
2 ℃ · 2℃
貯蔵温度
-20 °C · -20°C
溶解性
15 mg/mL、透明 · DMSO:可溶15mg/mL、透明
酸解離定数(Pka)
10.2 · 10.2(at 25℃)
外見
粉末または結晶
色
白からベージュ
水溶解度
8 mg/L · 8mg/L(温度表記なし)
Merck
14 · 14,3521
Henry's Law Constant
1.4 · 1.4×103 mol/(m3Pa) at 25℃, HSDB (2015)
BCS Class
4 · 4
InChI
1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1
InChIKey
XPOQHMRABVBWPR-ZDUSSCGKSA-N
SMILES
ClC1=CC=C2C([C@@](C#CC3CC3)(C(F)(F)F)OC(N2)=O)=C1
EPAの化学物質情報
2 H-3,1-Benzoxazin-2-one, · 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)- (154598-52-4)

化学的性質

化学的特性White to Slightly Pink Crystalline Powder

Body BurdenEfavirenz is distributed into human milk.
Interactions · 5 件

Alcohol abuse complicates treatment of HIV disease and is linked to poor outcomes. Alcohol pharmacotherapies, including disulfiram (DIS), are infrequently utilized in co-occurring HIV and alcohol use disorders possibly related to concerns about drug interactions between antiretroviral (ARV) medications and DIS. This pharmacokinetics study (n?=?40) examined the effect of DIS on efavirenz (EFV), ritonavir (RTV), or atazanavir (ATV) and the effect of these ARV medications on DIS metabolism and aldehyde dehydrogenase (ALDH) activity which mediates the DIS-alcohol reaction. EFV administration was associated with decreased S-Methyl-N-N-diethylthiocarbamate (DIS carbamate), a metabolite of DIS (p?=?.001) and a precursor to the metabolite responsible for ALDH inhibition, S-methyl-N,N-diethylthiolcarbamate sulfoxide (DETC-MeSO). EFV was associated with increased DIS inhibition of ALDH activity relative to DIS alone administration possibly as a result of EFV-associated induction of CYP 3A4 which metabolizes the carbamate to DETC-MeSO (which inhibits ALDH). Conversely, ATV co-administration reduced the effect of DIS on ALDH activity possibly as a result of ATV inhibition of CYP 3A4. DIS administration had no significant effect on any ARV studied.

Administration of efavirenz in patients receiving psychoactive drugs may result in increased CNS effects.

Efavirenz may decrease the plasma concentrations of amprenavir; no specific dosage adjustment can be recommended until additional studies are conducted.

Efavirenz may inhibit the metabolism of these medications /astemizole or cisapride/ through competition for the CYP3A4 isoenzyme, which may increase the potential for cardiac arrhythmias; use is contraindicated.

For more Interactions (Complete) data for EFAVIRENZ (15 total), please visit the HSDB record page.

Hepatotoxicity · 1 件

Serum aminotransferase elevations above 5 times the upper limit of normal occur in 1% to 8% of patients on efavirenz, and this rate is higher in patients who have HCV coinfection. Clinically apparent hepatotoxicity due to efavirenz is rare, but many convincing cases have been published. The liver injury is usually immunoallergic in pattern and arises within 1 to 8 weeks of starting therapy. Signs of hypersensitivity are less common than with nevirapine hepatotoxicity, but symptoms can include rash, fever, and eosinophilia and sometimes facial edema, lymphadenoapthy and lymphocytosis (Cases 1 and 2). Autoantibody formation is rare. The serum enzyme pattern is variable, typically cholestatic or mixed, but sometimes hepatocellular, these cases being more severe, likely to show submassive necrosis on liver biopsy and associated with a high fatality rate. In general, however, recovery is rapid upon stopping therapy.

Environmental Fate · 3 件

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 17,000(SRC), determined from a structure estimation method(2), indicates that efavirenz is expected to be immobile in soil(SRC). Volatilization of efavirenz from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 7.0X10-9 atm-cu m/mole(SRC), using a fragment constant estimation method(3). Efavirenz is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 3.8X10-7 mm Hg at 25 °C(SRC), determined from a fragment constant method(4). Biodegradation data in soil were not available(SRC, 2013).

AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 17,000(SRC), determined from a structure estimation method(2), indicates that efavirenz is expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 7.0X10-9 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). According to a classification scheme(5), an estimated BCF of 580(SRC), from an estimated log Kow of 4.69(2) and a regression-derived equation(2), suggests the potential for bioconcentration in aquatic organisms is high(SRC). Efavirenz may undergo hydrolysis in the environment due to the presence of functional groups that hydrolyze under environmental conditions(3). Biodegradation data in water were not available(SRC, 2013).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), efavirenz, which has an estimated vapor pressure of 3.8X10-7 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase efavirenz is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 8 hours(SRC), calculated from its rate constant of 4.2X10-11 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(3). Particulate-phase efavirenz may be removed from the air by wet or dry deposition(SRC). Efavirenz contains chromophores that absorb at wavelengths >290 nm(4) and, therefore, may be susceptible to direct photolysis by sunlight(SRC).

Adverse Effects · 1 件

As a drug class, NNRTIs are commonly associated with central nervous system (CNS) effects. These effects include impaired concentration, vivid or abnormal dreams, insomnia, suicidal ideation, nausea, and vomiting. Patients who experience these adverse effects are more likely to be non-adherent and discontinue their antiretroviral therapy, leading to anti-virologic therapeutic failure. These symptoms typically arise in the first few days of treatment and decline within a few weeks of continued therapy. Lipodystrophy is also a common adverse effect of all NNRTIs and may occur during treatment with efavirenz. Other commonly encountered adverse events include rash, elevated AST or ALT, decreased neutrophils, hyperglycemia, and hyperlipidemia.

Milk ConcentrationsEfavirenz is distributed into human milk.
Toxicity Summary · 1 件

The toxicity of this drug is generally relative to serum concentrations. Overdose is uncommon, and life-threatening sequelae from acute overdose are rare. There is no antidote available for efavirenz overdose. Short-term toxicity is usually transient and does not require treatment interruption.

Ongoing Test Status · 1 件

The following link will take the user to the National Toxicology Program (NTP) Test Agent Search Results page, which tabulates all of the "Standard Toxicology & Carcinogenesis Studies", "Developmental Studies", and "Genetic Toxicity Studies" performed with this chemical. Clicking on the "Testing Status" link will take the user to the status (i.e., in review, in progress, in preparation, on test, completed, etc.) and results of all the studies that the NTP has done on this chemical.[Available from, as of November 15, 2013: http://ntp-apps.niehs.nih.gov/ntp_tox/index.cfm?fuseaction=ntpsearch.searchresults&searchterm=154598-52-4]

Soil Adsorption/Mobility · 1 件

Using a structure estimation method based on molecular connectivity indices(1), the Koc of efavirenz can be estimated to be 17,000(SRC). According to a classification scheme(2), this estimated Koc value suggests that is expected to be immobile in soil.

Human Toxicity Excerpts · 5 件

/HUMAN EXPOSURE STUDIES/ As efforts intensify to eliminate perinatal HIV transmission, understanding kinetics of maternal-to-child transfer of antiretrovirals during pregnancy and breastfeeding is critical. Antiretroviral levels in plasma, cord blood, and breastmilk reflect exposure over short intervals. Hair concentrations reflect cumulative exposure and can uniquely quantify in utero transfer of maternal medications to infants. We measured plasma and hair antiretroviral levels in HIV-infected Ugandan mothers and their infants at delivery and during breastfeeding to assess transfer. HIV-infected pregnant women were randomized to lopinavir/ritonavir- or efavirenz-based therapy in a larger trial (the Prevention of Malaria and HIV disease in Tororo, PROMOTE). At 0, 8, and 12 weeks postpartum, plasma antiretroviral levels were measured in 117 mother-infant pairs; hair levels were assayed at 12 weeks. Ratios and correlations of infant:maternal concentrations were calculated. By 12 weeks, 90.4% of mothers reported exclusive breastfeeding. ... Moderate transfer of efavirenz occurs during pregnancy and breastfeeding (40% cumulative; 15% during breastfeeding). Despite differences in exposure, no infant seroconversions or correlations between infant hair/plasma antiretroviral levels and adverse effects were observed. Using a unique approach combining hair and plasma data, we found that different antiretrovirals have distinct kinetics of mother-to-infant transfer. Efavirenz transfers during both pregnancy and breastfeeding, whereas lopinavir and ritonavir transfer only in utero. Further study of the degree and timing of maternal-to-child transfer by antiretroviral will help optimize strategies that protect infants and minimize toxicities during periods of risk.

/HUMAN EXPOSURE STUDIES/ Substantial increases in serum concentrations of AST (SGOT) or ALT (SGPT) (more than 5 times the upper limit of normal) occurred in 3% of evaluated adults receiving efavirenz in clinical studies; the frequency of increases in AST or ALT in patients receiving efavirenz was similar to that in patients receiving regimens that did not include efavirenz. In patients who were seropositive for hepatitis B and/or C, substantial increases in serum concentrations of AST or ALT (more than 5 times the upper limit of normal) occurred in 7 or 8%, respectively, of adults receiving efavirenz and in 5 or 4%, respectively, of adults receiving regimens that did not include efavirenz. Increases in Gamma-glutamyltransferase (GGT, GGPT) (more than 5 times the upper limit of normal) occurred in 4% of patients receiving efavirenz in clinical studies, in 1.5-2% of patients receiving regimens that did not include efavirenz, and in 10% of those receiving efavirenz who were seropositive for hepatitis B and/or C. Isolated increases in GGT (i.e., increases in GGT without increases in AST and ALT) in patients receiving efavirenz may reflect drug-induced enzyme induction rather than liver toxicity. Hepatic failure and hepatitis have been reported during postmarketing surveillance.

Artificial Pollution SourcesEfavirenz's production and use as an antiviral(1) may result in its release to the environment through various waste streams(SRC).
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Efavirenz

vMost-DILI-concern

7

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

法規制情報

FDA Requirements · 1 件

The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including efavirenz, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

安全データ

wgk
3
rtecs
DM3440000
ridadr
UN3082 - class 9 - PG 3 - DOT NA1993 - Environmentally hazardous substances, liquid, n.o.s. HI: all (not BR)
hs_code
2934990002
risk_code
50
hazard_code
N
safety_code
61
Hazard Classifications
Acute Tox. 4 OralAquatic Acute 1Aquatic Chronic 1Repr. 1B
ストレージクラス
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
有毒物質データの
154598-52-4(Hazardous Substances Data)

The terminal elimination half-life of efavirenz reported in single-dose studies is longer than that reported in multiple-dose studies and has averaged 52-76 hours after a single oral dose and 40-55 hours following administration of 200-400 mg daily for 10 days.

Metabolism/Metabolites · 4 件

Efavirenz is principally metabolized by the cytochrome P450 system to hydroxylated metabolites with subsequent glucuronidation of these hydroxylated metabolites. These metabolites are essentially inactive against HIV-1.

Efavirenz was metabolized extensively by all the species as evidenced by the excretion of none or trace quantities of parent compound in urine. Significant species differences in the metabolism of efavirenz were observed. The major metabolite excreted in the urine of all species was the O-glucuronide conjugate (M1) of the 8-hydroxylated metabolite. Efavirenz was also metabolized by direct conjugation with glucuronic acid, forming the N-glucuronide (M2) in all five species. The sulfate conjugate of 8-OH efavirenz (M3) was found in the urine of rats and cynomolgus monkeys but not in humans. In addition to the aromatic ring-hydroxylated products, metabolites with a hydroxylated cyclopropane ring (at C14) were also isolated. GSH-related products of efavirenz were identified in rats and guinea pigs. The cysteinylglycine adduct (M10), formed from the GSH adduct (M9), was found in significant quantities in only rat and guinea pig urine and was not detected in other species. In vitro metabolism studies were conducted to show that the GSH adduct was produced from the cyclopropanol intermediate (M11) in the presence of only rat liver and kidney subcellular fractions and was not formed by similar preparations from humans or cynomolgus monkeys. These studies indicated the existence of a specific glutathione-S-transferase in rats capable of metabolizing the cyclopropanol metabolite (M11) to the GSH adduct, M9.

Efavirenz is a substrate for cytochrome p450 isoforms, particularly CYP3A4 and CYP2B6. The 8-hydroxy metabolite is excreted in the urine, and the glucuronide conjugate of 8-hydroxy-efavirenz is present in plasma and urine. Sixty percent of the dose is excreted in urine as the glucuronide conjugate.

Efavirenz has known human metabolites that include 8-hydroxyefavirenz.

FDA Pharmacological Classification · 6 件

JE6H2O27P8

EFAVIRENZ

Established Pharmacologic Class [EPC] - Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor

Non-Nucleoside Analog [EXT]

Mechanisms of Action [MoA] - Non-Nucleoside Reverse Transcriptase Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 3A Inducers

MeSH Pharmacological Classification · 5 件

Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template.

Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2C9.

Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2C19.

Drugs and compounds that induce the synthesis of CYTOCHROME P-450 CYP2B6.

Drugs and compounds that induce the synthesis of CYTOCHROME P-450 CYP3A.

Absorption, Distribution and Excretion · 6 件

Nearly all of the urinary excretion of the radiolabeled drug was in the form of metabolites.

Oral bioavailability of efavirenz may be affected by administration with food. Administration of a single 600-mg dose of efavirenz as capsules with a high-fat, high-calorie meal (894 kcal, 54 g fat, 54% of calories from fat) or a reduced-fat, normal-calorie meal (440 kcal, 2 g fat, 4% of calories from fat) increases peak plasma concentrations of the drug by 39 or 51%, respectively, and AUC by 22 or 17%, respectively, compared with administration in the fasting state. Administration of a single 600-mg dose of efavirenz as tablets with a high-fat, high-calorie meal (approximately 1000 kcal, 500-600 kcal from fat) increases peak plasma concentrations and AUC of the drug by 79 and 28%, respectively, compared with administration in the fasting state.

Efavirenz is excreted principally in the feces, both as unchanged drug and metabolites. Excretion of efavirenz has been evaluated in individuals receiving 400 mg daily for 1 month. Following oral administration of 400 mg of radiolabeled efavirenz on day 8, 14-34% of the dose was excreted in urine (less than 1% as unchanged drug), and 16-61% was excreted in feces (predominantly as unchanged drug).

Efavirenz is about 99.5-99.75% bound to plasma proteins, principally albumin.

In HIV-infected adults receiving efavirenz 200, 400, or 600 mg once daily, peak plasma concentrations of the drug generally occur in 3-5 hours and steady-state plasma concentrations are achieved in 6-10 days. Following continued administration of efavirenz, plasma concentrations are lower than expected from single-dose studies, presumably because of increased clearance of the drug. In one study in individuals receiving efavirenz 200-400 mg once daily for 10 days, plasma concentrations of the drug were 22-42% lower than those predicted from single-dose studies. Following oral administration of efavirenz 600 mg once daily in HIV-infected adults, peak plasma concentration, trough plasma concentration, and AUC of the drug at steady-state averaged 4.1 mcg/mL, 1.8 mcg/mL, and 58. mcg*hour/mL, respectively.

For more Absorption, Distribution and Excretion (Complete) data for EFAVIRENZ (8 total), please visit the HSDB record page.

Cellular LocationsMembrane
Metabolite PathwaysEfavirenz Action Pathway

用途と製造

Uses · 3 件

MEDICATION

Anti-HIV Agents; Reverse Transcriptase Inhibitors

Use (kg; approx.) in Germany (2009): >1000

Methods of ManufacturingPreparation: S. D. Young et al, European Patent Office 582455; eidem, United States of America patent 5519021 (1994, 1996 both to Merck & Co.)
Formulations/Preparations · 3 件

Oral: Capsules: 50 mg, Sustiva, Bristol-Myers Squibb, 100 mg, Sustiva, Bristol-Myers Squibb, 200 mg, Sustiva, Bristol-Myers Squibb; Tablets: 600 mg, Sustiva, Bristol-Myers Squibb

Oral: Tablets, film-coated: 600 mg with Emtricitabine, 200 mg and tenofovir, disoproxil fumarate 300 mg, Atripla (Bristol-Myers Squibb and Gilead). /Efavirenz combination/

Trade Name: Stocrin (Merck & Co)

応用分野 · 4 件

用途非ヌクレオチド系逆転写酵素 阻害剤です。逆転写酵素を阻害し、DNA 鎖の 伸長を停止することにより、ウイルスの増殖 を抑制します。

説明Efavirenz D5 was launched as Sustiva in the US for the treatment of infection by HIV, the virus causing AIDS, in combination with other anti-retroviral agents. Efavirenz D5 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) belonging to the 3,1-benzoxazin-2-one chemical class. It is the third non-nucleoside reverse transcriptase inhibitor to have been launched to date, after Nevirapine (1996) and Delavirdine (1997), increasing the arsenal of anti-HIV drugs for treating infected patients in dual or triple combination with nucleoside or other non-nucleoside RTIs, or protease inhibitors. Efavirenz D5 can be obtained by two related ways of six steps from 4-chloroaniline ; one of them is based on asymmetric synthesis by enantioselective addition of an acetylide to a trifluoroacetophenone. The anti-HIV activity of Efavirenz D5 was demonstrated against most wild-type and clinical strains of HIV-1, including those with the most frequently observed mutations. Efavirenz D5 has a better pharmacokinetic profile when compared with the preceding drugs of this class ; in particular, in a long-term experiment conducted in cynomolgus monkeys, Efavirenz D5 was shown to easily cross the blood brain barrier leading to an increase of the antiviral concentration in cerebrospinal fluid.

使用Efavirenz D5 is a nonnucleoside HIV-1 reverse transcriptase inhibitor. Antiviral

一般的な説明Efavirenz D5 (Sustiva)84 is also mandated for use with at leasttwo other antiretroviral agents. The compound is morethan 99% protein bound, and CSF concentrations exceedthe free fraction in the serum. Metabolism occurs in theliver. The half-life of a single dose of Efavirenz D5 is 52 to 76hours, and 40 to 55 after multiple doses (the drug inducesits own metabolism). Peak concentration is achieved in 3to 8 hours. Elimination is 14% to 34% in urine (as metabolites)and 16% to 41% in feces (primarily as Efavirenz D5).The oral dosage form is supplied as a capsule.

上流・下流製品情報

上流原料

シクロプロピルアセチレンクロロホルムトリフルオロ酢酸エチルピバロイルクロリド4-クロロアニリンブロモエタンブチルリチウムフラン4-ジメチルアミノピリジンエチルマグネシウムブロミド (39%エチルエーテル溶液, 約3mol/L)トリエチルアミン(-)-カンファン酸クロリド1,1'-カルボニルジイミダゾール[4-クロロ-2-[(1S)-3-シクロプロピル-1-ヒドロキシ-1-(トリフルオロメチル)-2-プロピニル)フェニル]カルバミン酸メチルエステル(S)-1-(2-Amino-5-chlorophenyl)-1-(trifluoromethyl)-3-cyclopropyl-2-propyn-1-ol炭酸ジフェニル

下流製品

Enantiomer Efavirenz
補足説明 · 1 件

定義ChEBI: 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor wit activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.

/HUMAN EXPOSURE STUDIES/ Although a causal relationship has not been established, pancreatitis has been reported in a few patients receiving efavirenz. In addition, asymptomatic increases in serum amylase concentrations to greater than 1.5 times the upper limit of normal have been reported in 10% of patients receiving efavirenz compared with 6% of patients in control groups not receiving the drug.

/SIGNS AND SYMPTOMS/ Rash has occurred in 26% of adults receiving efavirenz in clinical studies and in 18% of adults in control groups not receiving the drug. Although treatment-emergent rash generally manifests as mild to moderate maculopapular skin eruptions (NCI grade 1 and 2 reactions), rash associated with blistering, moist desquamation, or ulceration (NCI grade 3 reaction) has been reported in about 1% of adults receiving efavirenz in clinical studies. The incidence of grade 4 rash (e.g., erythema multiforme, Stevens-Johnson syndrome) in patients receiving efavirenz in clinical studies or in the expanded access program has been reported to be 0.1%.

For more Human Toxicity Excerpts (Complete) data for EFAVIRENZ (7 total), please visit the HSDB record page.